Insight Brief

3 Tools You Should Be Using Now to Improve Oncology Care through Minimal Residual Disease Testing

Minimal Residual Disease: Finding the Right Test for the New Definition of Remission

Measurement of residual disease (MRD) is one of the most reliable predictors of treatment outcomes for patients with leukemia, lymphoma, and myeloma. Because of this, global central laboratories like Q2 Solutions will have an increasingly important role to play in MRD testing.

In this complimentary insight brief you'll learn how 3 key technologies – Next Generation Sequencing, Flow Cytometry, and Polymerase Chain Reaction – help pharmaceutical and biotechnology companies predict better treatment outcomes through MRD testing.

Contact us today to discover how we can use our deep scientific expertise and global laboratory footprint to improve patient care in your MRD testing programs.


More Resources

Learn 3 Ways Anatomic Pathology Drives Advancements in Immuno-Oncology
Fighting Cancer: How Biomarker Testing and 3 Key Research Tools Shape Immunotherapy Drug Development
End-to-End Lab Services that Advance Oncology Research
View All